Carmine Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$13.7M
- Investors
-
7
Carmine Therapeutics General Information
Description
Developer of a gene therapy platform designed to generate a new class of medicines. The company's platform uses proprietary technology to generate a pipeline of gene therapies in the areas of hematology, oncology, and immunology by utilizing extracellular vesicles produced from red blood cells, enabling patients to overcome issues like the current limitations of viral-based gene therapies, such as immunogenicity, small transgene capacity, and manufacturing challenges.
Contact Information
Website
www.carminetherapeutics.comCorporate Office
- 150 CambridgePark Drive
- Suite 701
- Cambridge, MA 02140
- United States
Corporate Office
- 150 CambridgePark Drive
- Suite 701
- Cambridge, MA 02140
- United States
Carmine Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Early Stage VC (Series A) | 29-Nov-2022 | $13.7M | Completed | Product Development | ||
| 4. Early Stage VC (Series A) | 05-May-2021 | Completed | Product Development | |||
| 3. Seed Round | 17-Mar-2020 | Completed | Product Development | |||
| 2. Seed Round | 28-Aug-2019 | $3.4M | $3.4M | Completed | Product Development | |
| 1. Accelerator/Incubator | Completed | Product Development |
Carmine Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Seed-2 | ||||||||
| Seed-1 | 7,700,000 | $0.000100 | 8% | $0.25 | $0.25 | 1x | $0.25 | 33.82% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Carmine Therapeutics Comparisons
Industry
Financing
Details
Carmine Therapeutics Competitors (2)
One of Carmine Therapeutics’s 2 competitors is Disc Medicine, a Formerly VC-backed company based in Watertown, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Disc Medicine | Formerly VC-backed | Watertown, MA | ||||
| Aridis Pharmaceuticals | Formerly VC-backed | Los Gatos, CA |
Carmine Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Carmine Therapeutics Patents
Carmine Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024118073-A1 | Pulmonary delivery of nebulized preparations of red blood cell extracellular vesicles (rbcevs) | Inactive | 30-Nov-2022 | ||
| WO-2024025809-A1 | Cns delivery | Inactive | 23-Jul-2022 | ||
| WO-2023192624-A8 | Co-delivery of payload and promoting nucleic acids | Inactive | 31-Mar-2022 | ||
| WO-2023192624-A2 | Co-deuvery of payload and promoting nucleic acids | Inactive | 31-Mar-2022 | ||
| WO-2023192624-A3 | Co-deuvery of payload and promoting nucleic acids | Inactive | 31-Mar-2022 | C12N5/0641 |
Carmine Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Carmine Therapeutics Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cystic Fibrosis Foundation | Limited Partner | Minority | ||
| Huagai Capital | Venture Capital | Minority | ||
| Simcere Pharmaceutical Group | Corporation | Minority | ||
| Legend Star | Corporate Venture Capital | Minority | ||
| Takeda Pharmaceutical | Corporation | Minority |
Carmine Therapeutics FAQs
-
When was Carmine Therapeutics founded?
Carmine Therapeutics was founded in 2019.
-
Where is Carmine Therapeutics headquartered?
Carmine Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Carmine Therapeutics?
Carmine Therapeutics has 14 total employees.
-
What industry is Carmine Therapeutics in?
Carmine Therapeutics’s primary industry is Drug Discovery.
-
Is Carmine Therapeutics a private or public company?
Carmine Therapeutics is a Private company.
-
What is the current valuation of Carmine Therapeutics?
The current valuation of Carmine Therapeutics is .
-
What is Carmine Therapeutics’s current revenue?
The current revenue for Carmine Therapeutics is .
-
How much funding has Carmine Therapeutics raised over time?
Carmine Therapeutics has raised $33.7M.
-
Who are Carmine Therapeutics’s investors?
Cystic Fibrosis Foundation, Huagai Capital, Simcere Pharmaceutical Group, Legend Star, and Takeda Pharmaceutical are 5 of 7 investors who have invested in Carmine Therapeutics.
-
Who are Carmine Therapeutics’s competitors?
Disc Medicine and Aridis Pharmaceuticals are competitors of Carmine Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
